Day One Biopharmaceuticals Inc Total Liabilities
Day One Biopharmaceuticals Inc total liabilities. Based on the latest financial reports, Day One Biopharmaceuticals Inc (DAWN) has total liabilities worth $62.91 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Day One Biopharmaceuticals Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Day One Biopharmaceuticals Inc (2019–2024)
Total liabilities of Day One Biopharmaceuticals Inc from 2019 to 2024. This chart illustrates how Day One Biopharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check Day One Biopharmaceuticals Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Day One Biopharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Day One Biopharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Morgan Stanley Direct Lending Fund
NYSE:MSDL
|
USA | $2.13 Billion |
|
Sri Trang Agro-Industry Public Company Limited
BK:STA
|
Thailand | ฿47.56 Billion |
|
Nokian Renkaat Oyj
HE:TYRES
|
Finland | €1.30 Billion |
|
Playtech plc
F:PL8
|
Germany | €823.30 Million |
|
Sinomach Automobile Co Ltd
SHG:600335
|
China | CN¥27.05 Billion |
|
Cibus Nordic Real Estate AB (publ)
ST:CIBUS
|
Sweden | Skr1.85 Billion |
|
Maravai Lifesciences Holdings Inc
NASDAQ:MRVI
|
USA | $248.16 Million |
|
Shandong Denghai Seeds Co Ltd
SHE:002041
|
China | CN¥763.29 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Day One Biopharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see DAWN total asset value.
Liquidity & Leverage Metrics
Day One Biopharmaceuticals Inc Total Liabilities Ratios Explained
Day One Biopharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Day One Biopharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Day One Biopharmaceuticals Inc (2019–2024)
The table below shows the annual total liabilities of Day One Biopharmaceuticals Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $80.04 Million | +171.24% |
| 2023-12-31 | $29.51 Million | +73.34% |
| 2022-12-31 | $17.02 Million | +96.28% |
| 2021-12-31 | $8.67 Million | +294.23% |
| 2020-12-31 | $2.20 Million | -93.24% |
| 2019-12-31 | $32.52 Million | -- |
About Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory… Read more